Percentage of signal recovery (PSR): a more accurate marker than rCBV for differentiating radiation necrosis from tumor progression in brain metastases treated with stereotactic radiosurgery
Authors:
- Chen ZhouCZChen Zhou
- Zhao HuiZHZhao Hui
- AgustínAGAgustín
- Rafael D´ambrosiRDRafael D´ambrosi
- 29 October 2025
- journal article
- case study
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (1) , 1-10
Abstract
Purpose To compare the diagnostic performance of relative cerebral blood volume (rCBV) and percentage of signal recovery (PSR), both derived from dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI), in distinguishing tumor progression from radiation necrosis in brain metastases that have been treated with stereotactic radiosurgery (SRS). Methods This retrospective, single-centre study analysed 96 brain metastases with post-radiotherapy increase in contrast enhancement. The lesions were classified as tumor progression (n = 46) or radiation necrosis (n = 50) based on histopathology and clinical evolution determined by consensus in the multidisciplinary committee. All patients underwent dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) with leakage correction and contrast preload, and rCBV was normalised to contralateral white matter. PSR was calculated from the T2* signal-time curve as (S1–Smin)/(S0–Smin). Diagnostic performance was assessed using ROC analysis and the Youden index. Results The median rCBV was significantly higher in tumor progression than in radiation necrosis (4.21 vs. 1.6; p < 0.001), whereas the PSR was significantly lower (59.58% vs. 88.61%, p < 0.001). AUC was 0.86 for rCBV and 0.99 for PSR. PSR outperformed rCBV (p = 0.0028, DeLong test). An optimal cut-off value for rCBV of 2.42 yielded 91.7% sensitivity and 72.2% specificity and for PSR of 68.8% yielded 95.8% sensitivity and 98.1% specificity. Conclusion PSR is more accurate than rCBV in distinguishing tumor progression versus radiation necrosis after SRS in brain metastases. PSR is a reliable, non-invasive biomarker that can improve clinical decision-making.Keywords
This publication has 46 references indexed in Scilit:
- Improved detection of brain metastases using contrast-enhanced 3D black-blood TSE sequences compared to post-contrast 3D T1 GRE: a comparative study on 1.5-T MRIEuropean Radiology, 2025
- Exploring the need for a preload on the estimation of permeability, vessel radius, and relative cerebral blood volume in MR vascular fingerprinting–based dynamic susceptibility contrast perfusion imagingMagnetic Resonance in Medicine, 2024
- Low rCBV values in glioblastoma tumor progression under chemoradiotherapyNeuroradiology, 2024
- Improved performance of non-preloaded and high flip-angle dynamic susceptibility contrast perfusion-weighted imaging sequences in the presurgical differentiation of brain lymphoma and glioblastomaEuropean Radiology, 2023
- Dynamic susceptibility MR perfusion in diagnosing recurrent brain metastases after radiotherapy: A systematic review and meta‐analysisJournal of Magnetic Resonance Imaging, 2019
- Observer variability of reference tissue selection for relativecerebral blood volume measurements in glioma patientsEuropean Radiology, 2018
- Assessing tumor cytoarchitecture using multiecho DSC‐MRI derived measures of the transverse relaxivity at tracer equilibrium (TRATE)Magnetic Resonance in Medicine, 2014
- Meningiomas with conventional MRI findings resembling intraaxial tumors: can perfusion-weighted MRI be helpful in differentiation?Neuroradiology, 2006
- T1Effects in Sequential Dynamic Susceptibility Contrast ExperimentsJournal of Magnetic Resonance, 1998
- Assessing tumor angiogenesis using macromolecular MR imaging contrast mediaJournal of Magnetic Resonance Imaging, 1997